Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery

Domingues, Inês; Leclercq, Isabelle A.; Beloqui, Ana

doi:10.1016/j.jconrel.2023.09.040

Cited by 20 publications

(4 citation statements)

References 185 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the advancement and breakthroughs in nanomedicine technology, nucleic acid drugs are emerging as a promising therapeutic approach. − Several studies have already confirmed the efficacy of siRNA-based therapeutic strategies in improving MAFLD. , This improvement is particularly notable when employing lipid-based nanocarriers. Similar to siRNA therapy, mRNA-based strategies also involve the regulation of gene expression and can utilize the same carriers for nucleic acid delivery.…”

Section: Types Of Liver Diseasesmentioning

confidence: 99%

“…However, liver diseases, encompassing fatty liver, hepatitis, liver fibrosis, and hepatocellular carcinoma (HCC), pose significant challenges to global health authorities. − These conditions can arise from viral infections, alcohol abuse, obesity, and unhealthy dietary habits. Generally, pharmacotherapy, surgical resection, and liver transplantation are the traditional treatment options, but they face a series of problems such as poor efficacy, strong side effects, and high cost. − In light of these challenges, it is imperative to seek innovative strategies that enhance the management of liver diseases.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Emerging mRNA Technology for Liver Disease Therapy

Wang,

Fang,

Luo

et al. 2024

ACS Nano

View full text Add to dashboard Cite

Liver diseases have consistently posed substantial challenges to global health. It is crucial to find innovative methods to effectively prevent and treat these diseases. In recent times, there has been an increasing interest in the use of mRNA formulations that accumulate in liver tissue for the treatment of hepatic diseases. In this review, we start by providing a detailed introduction to the mRNA technology. Afterward, we highlight types of liver diseases, discussing their causes, risks, and common therapeutic strategies. Additionally, we summarize the latest advancements in mRNA technology for the treatment of liver diseases. This includes systems based on hepatocyte growth factor, hepatitis B virus antibody, left−right determination factor 1, human hepatocyte nuclear factor α, interleukin-12, methylmalonyl-coenzyme A mutase, etc. Lastly, we provide an outlook on the potential of mRNA technology for the treatment of liver diseases, while also highlighting the various technical challenges that need to be addressed. Despite these difficulties, mRNA-based therapeutic strategies may change traditional treatment methods, bringing hope to patients with liver diseases.

show abstract

Section: Types Of Liver Diseasesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Emerging mRNA Technology for Liver Disease Therapy

Wang,

Fang,

Luo

et al. 2024

ACS Nano

View full text Add to dashboard Cite

show abstract

“…Over the last two decades, numerous clinical trials have investigated targets in the development of drugs for non-alcoholic steatohepatitis (NASH). However, owing to the disease’s inherent heterogeneity and the intricate nature of its pathogenesis, few drugs have yet received approval for clinical intervention[ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Current perspectives on mesenchymal stem cells as a potential therapeutic strategy for non-alcoholic fatty liver disease

Jiang,

Yusoff,

et al. 2024

World J Stem Cells

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant health challenge, characterized by its widespread prevalence, intricate natural progression and multifaceted pathogenesis. Although NAFLD initially presents as benign fat accumulation, it may progress to steatosis, non-alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. Mesenchymal stem cells (MSCs) are recognized for their intrinsic self-renewal, superior biocompatibility, and minimal immunogenicity, positioning them as a therapeutic innovation for liver diseases. Therefore, this review aims to elucidate the potential roles of MSCs in alleviating the progression of NAFLD by alteration of underlying molecular pathways, including glycolipid metabolism, inflammation, oxidative stress, endoplasmic reticulum stress, and fibrosis. The insights are expected to provide further understanding of the potential of MSCs in NAFLD therapeutics, and support the development of MSC-based therapy in the treatment of NAFLD.

show abstract

“…While its typical characteristic include excessive lipid accumulation in the liver without alcohol abuse, some NAFLD patients can further progress to nonalcoholic steatohepatitis, liver fibrosis, cirrhosis, and eventually hepatocellular carcinoma. The number of individuals at risk for this serious consequence is steadily increasing ( 3 , 4 ). Although NAFLD involves complex risk factors, its prevalence is usually associated with obesity ( 5 – 7 ).…”

Section: Introductionmentioning

confidence: 99%

Association between triglyceride to high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease and liver fibrosis in American adults: an observational study from the National Health and Nutrition Examination Survey 2017–2020

Wang,

Li,

Wang

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectiveThis study investigated the link between triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio and nonalcoholic fatty liver disease (NAFLD) and liver fibrosis in American adults.MethodsInformation for 6495 participants from the National Health and Nutrition Examination Survey (NHANES) 2017–2020.03 was used for this cross-sectional study. The link between TG/HDL-C ratios and NAFLD and liver fibrosis was assessed by multiple linear regression before evaluating nonlinear correlations based on smoothed curve fitting models. Stratification analysis was then applied to confirm whether the dependent and independent variables displayed a stable association across populations.ResultsTG/HDL-C ratios were positively correlated with NAFLD, with higher ratios being linked to increased prevalence of NAFLD. After adjusting for potential confounders, the odds ratios (OR) for NAFLD patients in the fourth TG/HDL-C quartile were 3.61 (95% confidence interval [CI], 2.94–4.38) (P for trend < 0.001) in comparison with those in the first quartile after adjusting for clinical variables. However, no statistical significance was noted for the ratio for liver fibrosis after adjusting for potential confounders (P for trend = 0.07). A nonlinear correlation between TG/HDL-C ratios and NAFLD was observed based on smoothed curve fitting models. However, a nonlinear relationship between the ratios and liver fibrosis was not established. In subgroup analyses, there was an interaction between smoking status and TG/HDL-C ratio in relation to the prevalence of liver fibrosis (P for interaction < 0.001).ConclusionsAmong American adults, the TG/HDL-C ratio was noted to be nonlinearly positively associated with the prevalence of NAFLD; however, this relationship was not present in liver fibrosis.

show abstract

Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery

Cited by 20 publications

References 185 publications

Emerging mRNA Technology for Liver Disease Therapy

Emerging mRNA Technology for Liver Disease Therapy

Current perspectives on mesenchymal stem cells as a potential therapeutic strategy for non-alcoholic fatty liver disease

Association between triglyceride to high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease and liver fibrosis in American adults: an observational study from the National Health and Nutrition Examination Survey 2017–2020

Contact Info

Product

Resources

About